ArticleCNS neuroscience & therapeutics2026
Esketamine Preserves Network Connectivity and Promotes Recovery in Consciousness Disorders.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDisorders of consciousness (DoC) present significant therapeutic challenges with limited effective interventions. The choice of anesthetic agent during procedures such as spinal cord stimulation may influence long-term neurological outcomes, yet comparative evidence is scarce. This prospective, non-randomized, comparative effectiveness trial investigated the neurophysiological and clinical effects of esketamine versus propofol in patients with DoC.
methodsIn this prospective, non-randomized trial, 34 adult DoC patients undergoing spinal cord stimulator implantation were allocated to receive either esketamine (n = 17) or propofol (n = 17) as the primary anesthetic, based on clinical practice. Multimodal assessments included the Coma Recovery Scale-Revised (CRS-R) at baseline and 3-month follow-up, along with high-density electroencephalography (EEG) to analyze permutation entropy (PE) and weighted phase lag index (wPLI). Multivariable regression adjusted for key confounders.
resultsCompared to propofol, esketamine was associated with significantly faster recovery of spontaneous respiration (12.02 ± 3.88 vs. 17.42 ± 4.62 min, p = 0.005) and reduced need for intraoperative vasopressors (17.65% vs. 52.94%, p = 0.034). EEG analysis revealed that esketamine better preserved brain electrical complexity (higher permutation entropy during maintenance, p < 0.001) and maintained higher functional connectivity, particularly in the gamma band (weighted phase lag index, p = 0.054).
conclusionEsketamine demonstrates superior neurophysiological preservation over propofol in patients with disorders of consciousness, maintaining neural complexity and gamma-band connectivity during anesthesia. These mechanisms are associated with accelerated respiratory recovery, hemodynamic stability, and significantly improved consciousness outcomes at 3 months, supporting its potential as a neuroprotective anesthetic in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.